Furthermore, the development of peptides that modulate apoptotic pathways, particularly those that target anti-apoptotic proteins like Bcl-2 and Bcl-XL, has shown promise in reversing apoptosis evasion, a key mechanism of resistance in Tx-treated cancer cells. This evidence concerns the gene BCL2L1 and cancer.